Search

Displaying results 3121 - 3130 of 10000 in total
  1. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist.

  2. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    It is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … Antineoplastic effects and potential uses of somatostatin on various tumours, including pituitary adenomas, GEP-NETs, paragangliomas, carcinoids, breast cancers, malignant lymphoma and small-cell lung

  3. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

  4. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine. … Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine.

    Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
  5. Drug

    Zofenopril

    go.drugbank.com/drugs/DB13166
    ApprovedInvestigational

    It is an angiotensin-converting enzyme (ACE) inhibitor.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

  7. Drug

    Dextranomer

    go.drugbank.com/drugs/DB13560
    Investigational

    Categories: Compounds used in a research, industrial, or household setting, Preparations for Treatment of Wounds and Ulcers
  8. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833] … Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication.

  9. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. … Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.

  10. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … [L64098] It is a synthetic cyclic peptide that blocks the iron transporter ferroportin, reducing the availability of iron for red blood cell production and lowering hematocrit.